BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23859777)

  • 21. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells.
    Radanyi C; Le Bras G; Marsaud V; Peyrat JF; Messaoudi S; Catelli MG; Brion JD; Alami M; Renoir JM
    Cancer Lett; 2009 Feb; 274(1):88-94. PubMed ID: 18842335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone.
    Mays JR; Hill SA; Moyers JT; Blagg BS
    Bioorg Med Chem; 2010 Jan; 18(1):249-66. PubMed ID: 19932969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.
    Kusuma BR; Duerfeldt AS; Blagg BS
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7170-4. PubMed ID: 22014546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.
    Zhao H; Donnelly AC; Kusuma BR; Brandt GE; Brown D; Rajewski RA; Vielhauer G; Holzbeierlein J; Cohen MS; Blagg BS
    J Med Chem; 2011 Jun; 54(11):3839-53. PubMed ID: 21553822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer activity of methylene blue via inhibition of heat shock protein 70.
    Sanchala D; Bhatt LK; Pethe P; Shelat R; Kulkarni YA
    Biomed Pharmacother; 2018 Nov; 107():1037-1045. PubMed ID: 30257315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.
    Garg G; Zhao H; Blagg BS
    Bioorg Med Chem; 2017 Jan; 25(2):451-457. PubMed ID: 27914946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.
    Matthews SB; Vielhauer GA; Manthe CA; Chaguturu VK; Szabla K; Matts RL; Donnelly AC; Blagg BS; Holzbeierlein JM
    Prostate; 2010 Jan; 70(1):27-36. PubMed ID: 19739131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of Hsf1 activity by novobiocin and geldanamycin.
    Conde R; Belak ZR; Nair M; O'Carroll RF; Ovsenek N
    Biochem Cell Biol; 2009 Dec; 87(6):845-51. PubMed ID: 19935870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.
    Byrd KM; Kent CN; Blagg BSJ
    ChemMedChem; 2017 Dec; 12(24):2022-2029. PubMed ID: 29058824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
    Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A library of noviosylated coumarin analogues.
    Huang YT; Blagg BS
    J Org Chem; 2007 May; 72(10):3609-13. PubMed ID: 17328573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32.
    Chatterjee BK; Jayaraj A; Kumar V; Blagg B; Davis RE; Jayaram B; Deep S; Chaudhuri TK
    J Biol Chem; 2019 Apr; 294(16):6450-6467. PubMed ID: 30792306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
    Malayeri SO; Abnous K; Arab A; Akaberi M; Mehri S; Zarghi A; Ghodsi R
    Bioorg Med Chem; 2017 Feb; 25(3):1294-1302. PubMed ID: 28073608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
    Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD
    Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.